Accuray (NASDAQ:ARAY) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Accuray (NASDAQ:ARAY) was downgraded from a "hold" rating to a "sell" rating by analysts at Wall Street Zen.
• Despite the downgrade, BTIG Research raised their price target for Accuray from $4.00 to $5.00 and maintained a "buy" rating, indicating mixed analyst sentiment.
• Accuray reported earnings of $0.01 per share, missing the consensus estimate by $0.02, while their revenue for the quarter was $127.54 million, surpassing expectations.

Wall Street Zen lowered shares of Accuray (NASDAQ:ARAY - Free Report) from a hold rating to a sell rating in a research report report published on Saturday.

Separately, BTIG Research lifted their price objective on Accuray from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Accuray presently has a consensus rating of "Buy" and an average target price of $5.00.

Accuray Trading Down 1.0%

NASDAQ:ARAY traded down $0.02 during trading hours on Friday, hitting $1.48. 237,852 shares of the company were exchanged, compared to its average volume of 762,449. The stock has a market capitalization of $166.20 million, a price-to-earnings ratio of -73.75 and a beta of 1.26. The company has a current ratio of 1.65, a quick ratio of 0.92 and a debt-to-equity ratio of 1.53. Accuray has a one year low of $1.14 and a one year high of $2.95. The company has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $1.56.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%.The business had revenue of $127.54 million during the quarter, compared to the consensus estimate of $123.78 million. Accuray has set its FY 2026 guidance at EPS. Sell-side analysts expect that Accuray will post 0.01 EPS for the current fiscal year.

Institutional Trading of Accuray

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARAY. Wells Fargo & Company MN increased its holdings in Accuray by 37.7% during the 4th quarter. Wells Fargo & Company MN now owns 260,071 shares of the medical equipment provider's stock worth $515,000 after purchasing an additional 71,198 shares in the last quarter. Barclays PLC boosted its stake in shares of Accuray by 7.6% in the 4th quarter. Barclays PLC now owns 226,812 shares of the medical equipment provider's stock worth $449,000 after buying an additional 15,993 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Accuray by 38.3% in the 4th quarter. MetLife Investment Management LLC now owns 48,234 shares of the medical equipment provider's stock worth $96,000 after buying an additional 13,370 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Accuray in the 4th quarter worth approximately $66,000. Finally, Northern Trust Corp boosted its stake in shares of Accuray by 0.9% in the 4th quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider's stock worth $1,603,000 after buying an additional 7,399 shares during the last quarter. 64.08% of the stock is owned by institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.